PCOS renamed P.M.O.S. in global push for better diagnosis, care

The name change from PCOS to P.M.O.S. is meant to do something practical, not symbolic: make a disorder that affects about 1 in 8 women worldwide easier to recognize, diagnose and treat. The new term, polyendocrine metabolic ovarian syndrome, was announced on May 12, 2026 in a global consensus paper published in The Lancet after a 14-year effort led by Helena Teede of Monash University.

The renaming drew on input from more than 50 academic, clinical and patient organizations, along with feedback from more than 14,000 to 22,000 women and health professionals across the world. It was unveiled at the 8th European Congress of Endocrinology in Prague. Supporters say the old label, polycystic ovary syndrome, misled patients and doctors alike by suggesting ovarian cysts were the defining feature, when they are not.

That point matters because the condition is not confined to the ovaries. Researchers say it is tied to hormonal shifts, metabolic problems, mental health symptoms, skin changes, weight changes and reproductive effects, with long-term risks that include type 2 diabetes and cardiovascular disease. A related paper found no increase in abnormal ovarian cysts in the condition, further undercutting the old name.

The Endocrine Society says the disorder affects more than 170 million women globally, and estimates in the United States put the number at 5 million to 6 million women. Up to 70% of cases may go undiagnosed, a gap that advocates and clinicians have linked to confusion over symptoms and the narrow focus implied by the old terminology.

The diagnosis itself does not change with the new name. Doctors will still rely on the same core criteria: irregular periods or absent ovulation, signs of excess androgens such as acne, excess body or facial hair, or hair loss, and ultrasound evidence of multiple follicles or ovarian findings consistent with the syndrome. That means the rename does not rewrite who qualifies for the condition, but it could change how quickly patients are identified and how seriously their symptoms are taken.

The bigger test will be whether P.M.O.S. changes care outside the clinic room. By giving the condition a name that reflects its endocrine and metabolic burden, experts hope to reduce stigma, improve public understanding and push policy makers to treat it as a common but historically neglected chronic disease rather than a misunderstood reproductive problem.